believ pipelin believ
sale larg in-line initi guidanc bit light
commentari acceler growth year unfold slew new product
launch well better op margin cash convers suggest
thing upsw appreci execut strong suit
piec place still discount valuat peer
set seem good pt ep
slightli better sever issu still weigh
overal organ growth better expect despit
on-going headwind cvg weak pad paclitaxel issu lvad
launch competitor account chang servic steril issu
mitg still punki perform diabet offset
weak spot better perform rtg emerg market
cc em geographi sale contribut half growth
margin cash convers look
bottom line post op margin expans beat ep
despit absorb unplan china tariff expens neg
impact steril issu better cost contain play cash
convers post full year exceed long-term
initi guidanc come pipelin
initi sale guidanc littl light organ reflect aforement
challeng play earli year give way acceler growth
year unfold issu eb slew new product hit market
reiter surgic robot come year-end along laundri list
initi micra av low risk tavr linq aspir nv db non-adjunct
cgm etc growth expect near acceler
segment basi mitg rtg expect grow cvg
flat diabet full year mitg rtg cvg
diabet
get better good hand play valuat support
also support see margin expans though higher tax rate
off-set lower interest post refi suggest ep growth beyond
growth look remain rang even higher depend chunki
pipelin prospect play robot large-cap peer part grow
faster also trade ep versu pt
still discount ep appreci yet seen growth
acceler best executor piec place
valuat support outlook look
begin data present pro forma cash
basi includ covidien exclud amort
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
invest thesi base abil achiev mid-
expand product portfolio organ acquisit
achiev ep growth combin leverag
focus cost reduct
tct confer
pipelin regulatori mileston
sustain mid-single-digit top-lin growth next
bp annual op margin expans
volum growth augment new product
entri new market
continu return annual form
dividend buyback
tuck-in acquisit bake base assumpt
pt base adjust ep
sustain mid high-single-digit top-lin growth
volum growth augment new product
entri new market
annual op margin expans
continu return annual form
dividend buyback
large-scal accret bake bull assumpt
pt base adjust ep
overal top-lin growth deceler low-singl digit
next year
volum deceler off-set new product
entri new market
profil erod return diminish
annual
pt base adjust ep
pleas see import disclosur inform page report
financi summari market data
estim valuat
begin data present pro forma cash basi includ covidien exclud amort
pleas see import disclosur inform page report
diabet weak comp guidanc look light
one area linger question diabet segment slow
expect slowdown tough comp due anniversari
bolu patient last year weak expect extend stabil
combin stand-alon cgm sensor sale presum better pump sale
expect improv time rang add easier
meal time calcul better connect includ remot softwar updat still
guidanc beg question faster given market
explod diabet technolog improv portfolio scale
pleas see import disclosur inform page report
pleas see import disclosur inform page report
eaprjuloctjanapraprjuloctjanapraprapraprtot oper oper non-oper incom loss tax control net dilut share exhibit revenu model
pleas see import disclosur inform page report
pleas see import disclosur inform page report
